RituximabCaplacizumabThrombotic thrombocytopenic purpuracorticosteroidsplasma exchangeTTP
…nd corticosteroids, with relapses occurring in 20–50% of cases. Rituximab and caplacizumab (available since 2018) are currently used in c…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 272 of 2459dalbavancinABSSSIosteomyelitisspondylodiscitisacute bacterial skin and skin structure infectionsprosthetic joint infectionAmbulatory consolidation therapyHospital Pharmacy Departmentcomplex infections
…ults Thirty-seven patients were included; 97.3% (n=36) received dalbavancin off-label. The most frequent indications were prosthetic joint …
cefiderocolceftobiproleceftolozane/tazobactamceftazidime/avibactamceftarolinerenal impairmentmeropenem/vaborbactamsevere infectionsaztreonam/avibactam
…erapeutic Guidelines. Antibiotics studied: aztreonam/avibactam, cefiderocol, ceftaroline, ceftazidime/avibactam, ceftobiprole, ceftolozane/…
HIVUniversity HospitalcabotegravirLA-PrEPPrEP
…kground and Importance Pre-Exposure Prophylaxis (PrEP) is a key HIV prevention strategy. The recent introduction of long-acting inj…
migrainegalcanezumaberenumabfremanezumab
…n); 28 (90.3%) had chronic and 3 (9.7%) high-frequency episodic migraine. Second-line treatment was erenumab in 30 patients (96.9%) and …
tenofovir disoproxilemtricitabineHIVNational Health ServiceNHSItalian Medicines AgencyPrEPPre-exposure prophylaxisPrEP-related
…PrEP) is an antiretroviral therapy containing emtricitabine and tenofovir disoproxil used to prevent HIV infection. It can be administered as contin…
AtogepantNeurology DepartmentmigraineCMEthics Committee
…Most patients were women with CM and prior mAb–antiCGRP failure.Atogepant led to a significant but modest MDM/TDM reduction, consistent w…
ibrutinibvenetoclaxvenetoclax-inducedCLLchronic lymphocytic leukaemiaI+V
…ed apoptosis.The I+V regimen consists of three 28-day cycles of ibrutinib monotherapy, followed by the addition of venetoclax from cycle …
digoxinatrial fibrillationheart failuretertiary hospital
…en was 85,3±6.9 years and in men 81,4±8,9 years (p=0.174). Mean digoxin blood levels (nmol/L) were 3.6±1.8 in women and 3.5±2.1 in men …
severe paediatric asthmaomalizumabtezepelumabdupilumabmepolizumabSevere AsthmaBiologic therapiesPSAUbiologic therapyatopic dermatitis
…ermatitis. These findings reinforce the benefit of biologics in severe paediatric asthma and highlight the critical role of hospital pharmacists, in a P…
dupilumabmepolizumabtezepelumabreslizumabbenralizumabSUAnasal polyposisbiologic therapyatopic dermatitisbiologic treatment+1 more
…and nasal polyposis 29.2% (12/41). Biologic therapies used were dupilumab 48.7% (20/41), benralizumab 24.4% (10/41), tezepelumab 12.2% (5…
ibrutinibIBRCLLchronic lymphocytic leukaemiapharmaceutical care programprimary care hospital
…Background and Importance Although ibrutinib (IBR) is effective across all treatment lines for chronic lymph…